Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01104532 · ClinicalTrials.gov registry record · Phase 1

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects

A Phase 1 study, sponsored by Astellas Pharma.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target

NCT01104532: Completed Phase 1 study, sponsored by Astellas Pharma.

NCT01104532 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 64 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01104532, a Phase 1 study, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.

Interventions

  • DRUG sitagliptin
  • DRUG ASP1941

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2010-02
Est. Completion 2010-03
Phase Phase 1
Astellas Pharma

165 total trials

What the finished NCT01104532 record still lists

NCT01104532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which sitagliptin is the first listed.

NCT01104532 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01104532 about?

NCT01104532 is a clinical study titled "A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects". The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.

What is the current status of trial NCT01104532?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2010-02. Estimated completion is 2010-03.

What interventions are being tested in trial NCT01104532?

The interventions under investigation include: sitagliptin (DRUG), ASP1941 (DRUG).

Who is sponsoring clinical trial NCT01104532?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01104532's enrollment target sits among peer trials

64 808th of 2000 higher than 1,181 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01104532, the US trial registry maintained by the National Library of Medicine. NCT01104532 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.